Advertisement
| emerging technologies in pharmaceutical industry: Neuroscience Trials of the Future National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, 2016-11-07 On March 3-4, 2016, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop in Washington, DC, bringing together key stakeholders to discuss opportunities for improving the integrity, efficiency, and validity of clinical trials for nervous system disorders. Participants in the workshop represented a range of diverse perspectives, including individuals not normally associated with traditional clinical trials. The purpose of this workshop was to generate discussion about not only what is feasible now, but what may be possible with the implementation of cutting-edge technologies in the future. |
| emerging technologies in pharmaceutical industry: Leading Pharmaceutical Innovation Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz, 2013-06-05 Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche. |
| emerging technologies in pharmaceutical industry: The Changing Economics of Medical Technology Institute of Medicine, Committee on Technological Innovation in Medicine, 1991-02-01 Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€as well as the involvement of numerous government agenciesâ€affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public. |
| emerging technologies in pharmaceutical industry: Emerging Technologies for Health and Medicine Dac-Nhuong Le, Chung Van Le, Jolanda G. Tromp, Gia Nhu Nguyen, 2018-10-16 Showcases the latest trends in new virtual/augmented reality healthcare and medical applications and provides an overview of the economic, psychological, educational and organizational impacts of these new applications and how we work, teach, learn and provide care. With the current advances in technology innovation, the field of medicine and healthcare is rapidly expanding and, as a result, many different areas of human health diagnostics, treatment and care are emerging. Wireless technology is getting faster and 5G mobile technology allows the Internet of Medical Things (IoMT) to greatly improve patient care and more effectively prevent illness from developing. This book provides an overview and review of the current and anticipated changes in medicine and healthcare due to new technologies and faster communication between users and devices. The groundbreaking book presents state-of-the-art chapters on many subjects including: A review of the implications of Virtual Reality (VR) and Augmented Reality (AR) healthcare applications A review of current augmenting dental care An overview of typical human-computer interaction (HCI) that can help inform the development of user interface designs and novel ways to evaluate human behavior to responses in VR and other new technologies A review of telemedicine technologies Building empathy in young children using augmented reality AI technologies for mobile health of stroke monitoring & rehabilitation robotics control Mobile doctor brain AI App An artificial intelligence mobile cloud computing tool Development of a robotic teaching aid for disabled children Training system design of lower limb rehabilitation robot based on virtual reality |
| emerging technologies in pharmaceutical industry: Biomimetic Medical Materials Insup Noh, 2018-11-23 This volume outlines the current status in the field of biomimetic medical materials and illustrates research into their applications in tissue engineering. The book is divided into six parts, focusing on nano biomaterials, stem cells, tissue engineering, 3D printing, immune responses and intellectual property. Each chapter has its own introduction and outlines current research trends in a variety of applications of biomimetic medical materials. The biomimetic medical materials that are covered include functional hydrogels, nanoparticles for drug delivery and medicine, the 3D bioprinting of biomaterials, sensor materials, stem cell interactions with biomaterials, immune responses to biomaterials, biodegradable hard scaffolds for tissue engineering, as well as other important topics, like intellectual property. Each chapter is written by a team of experts. This volume attempts to introduce the biomimetic properties of biomedical materials within the context of our current understanding of the nanotechnology of nanoparticles and fibres and the macroscopic aspects of 3D bioprinting. |
| emerging technologies in pharmaceutical industry: Emerging Technologies for Nanoparticle Manufacturing Jayvadan K. Patel, Yashwant V. Pathak, 2021-06-23 This book provides an overview of nanoparticle production methods, scale-up issues drawing attention to industrial applicability, and addresses their successful applications for commercial use. There is a need for a reference book which will address various aspects of recent progress in the methods of development of nanoparticles with a focus on polymeric and lipid nanoparticles, their scale-up techniques, and challenges in their commercialization. There is no consolidated reference book that discusses the emerging technologies for nanoparticle manufacturing. This book focuses on the following major aspects of emerging technologies for nano particle manufacturing. I. Introduction and Biomedical Applications of Nanoparticles II. Polymeric Nanoparticles III. Lipid Nanoparticles IV. Metallic Nanoparticles V. Quality Control for Nanoparticles VI. Challenges in Scale-Up Production of Nanoparticles VII. Injectable Nanosystems VIII. Future Directions and Challenges Leading scientists are selected as chapter authors who have contributed significantly in this field and they focus more on emerging technologies for nanoparticle manufacturing, future directions, and challenges. |
| emerging technologies in pharmaceutical industry: The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry Stephanie K. Ashenden, 2021-04-23 The Era of Artificial Intelligence, Machine Learning and Data Science in the Pharmaceutical Industry examines the drug discovery process, assessing how new technologies have improved effectiveness. Artificial intelligence and machine learning are considered the future for a wide range of disciplines and industries, including the pharmaceutical industry. In an environment where producing a single approved drug costs millions and takes many years of rigorous testing prior to its approval, reducing costs and time is of high interest. This book follows the journey that a drug company takes when producing a therapeutic, from the very beginning to ultimately benefitting a patient's life. This comprehensive resource will be useful to those working in the pharmaceutical industry, but will also be of interest to anyone doing research in chemical biology, computational chemistry, medicinal chemistry and bioinformatics. - Demonstrates how the prediction of toxic effects is performed, how to reduce costs in testing compounds, and its use in animal research - Written by the industrial teams who are conducting the work, showcasing how the technology has improved and where it should be further improved - Targets materials for a better understanding of techniques from different disciplines, thus creating a complete guide |
| emerging technologies in pharmaceutical industry: Innovation and Marketing in the Pharmaceutical Industry Min Ding, Jehoshua Eliashberg, Stefan Stremersch, 2013-10-31 The pharmaceutical industry is one of today’s most dynamic and complex industries, involving commercialization of cutting-edge scientific research, a huge web of stakeholders (from investors to doctors), multi-stage supply chains, fierce competition in the race to market, and a challenging regulatory environment. The stakes are high, with each new product raising the prospect of spectacular success—or failure. Worldwide revenues are approaching $1 trillion; in the U.S. alone, marketing for pharmaceutical products is, itself, a multi-billion dollar industry. In this volume, the editors showcase contributions from experts around the world to capture the state of the art in research, analysis, and practice, and covering the full spectrum of topics relating to innovation and marketing, including R&D, promotion, pricing, branding, competitive strategy, and portfolio management. Chapters include such features as: · An extensive literature review, including coverage of research from fields other than marketing · an overview of how practitioners have addressed the topic · introduction of relevant analytical tools, such as statistics and ethnographic studies · suggestions for further research by scholars and students The result is a comprehensive, state-of-the-art resource that will be of interest to researchers, policymakers, and practitioners, alike. |
| emerging technologies in pharmaceutical industry: 3D Printing of Pharmaceuticals Abdul W. Basit, Simon Gaisford, 2018-08-06 3D printing is forecast to revolutionise the pharmaceutical sector, changing the face of medicine development, manufacture and use. Potential applications range from pre-clinical drug development and dosage form design through to the fabrication of functionalised implants and regenerative medicine. Within clinical pharmacy practice, printing technologies may finally lead to the concept of personalised medicines becoming a reality. This volume aims to be the definitive resource for anyone thinking of developing or using 3D printing technologies in the pharmaceutical sector, with a strong focus on the translation of printing technologies to a clinical setting. This text brings together leading experts to provide extensive information on an array of 3D printing techniques, reviewing the current printing technologies in the pharmaceutical manufacturing supply chain, in particular, highlighting the state-of-the-art applications in medicine and discussing modern drug product manufacture from a regulatory perspective. This book is a highly valuable resource for a range of demographics, including academic researchers and the pharmaceutical industry, providing a comprehensive inventory detailing the current and future applications of 3D printing in pharmaceuticals. Abdul W. Basit is Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul’s research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. He leads a large and multidisciplinary research group, and the goal of his work is to further the understanding of gastrointestinal physiology by fundamental research. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which are currently in late-stage clinical trials. He has published over 350 papers, book chapters and abstracts and delivered more than 250 invited research presentations. Abdul is also a serial entrepreneur and has filed 25 patents and founded 3 pharmaceutical companies (Kuecept, Intract Pharma, FabRx). Abdul is a frequent speaker at international conferences, serves as a consultant to many pharmaceutical companies and is on the advisory boards of scientific journals, healthcare organisations and charitable bodies. He is the European Editor of the International Journal of Pharmaceutics. Abdul was the recipient of the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists (AAPS) and is the only non-North American scientist to receive this award. He was also the recipient of the Academy of Pharmaceutical Sciences (APS) award. Simon Gaisford holds a Chair in Pharmaceutics and is Head of the Department of Pharmaceutics at the UCL School of Pharmacy, University College London. He has published 110 papers, 8 book chapters and 4 authored books. His research is focused on novel technologies for manufacturing medicines, particularly using ink-jet printing and 3D printing, and he is an expert in the physico-chemical characterisation of compounds and formulations with thermal methods and calorimetry. |
| emerging technologies in pharmaceutical industry: Continuous Manufacturing for the Modernization of Pharmaceutical Production National Academies of Sciences, Engineering, and Medicine, Division on Earth and Life Studies, Board on Chemical Sciences and Technology, 2019-04-05 On July 30-31, 2018, the National Academies of Sciences, Engineering, and Medicine held a workshop titled Continuous Manufacturing for the Modernization of Pharmaceutical Production. This workshop discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics such as enzymes, monoclonal antibodies, and vaccines. The participants also discussed specific challenges for integration across the manufacturing system, including upstream and downstream processes, analytical techniques, and drug product development. The workshop addressed these challenges broadly across the biologics domain but focused particularly on drug categories of greatest FDA and industrial interest such as monoclonal antibodies and vaccines. This publication summarizes the presentations and discussions from the workshop. |
| emerging technologies in pharmaceutical industry: Modern Methods of Clinical Investigation Institute of Medicine, Committee on Technological Innovation in Medicine, 1990-02-01 The very rapid pace of advances in biomedical research promises us a wide range of new drugs, medical devices, and clinical procedures. The extent to which these discoveries will benefit the public, however, depends in large part on the methods we choose for developing and testing them. Modern Methods of Clinical Investigation focuses on strategies for clinical evaluation and their role in uncovering the actual benefits and risks of medical innovation. Essays explore differences in our current systems for evaluating drugs, medical devices, and clinical procedures; health insurance databases as a tool for assessing treatment outcomes; the role of the medical profession, the Food and Drug Administration, and industry in stimulating the use of evaluative methods; and more. This book will be of special interest to policymakers, regulators, executives in the medical industry, clinical researchers, and physicians. |
| emerging technologies in pharmaceutical industry: Sources of Medical Technology Committee on Technological Innovation in Medicine, Institute of Medicine, 1995-01-15 Evidence suggests that medical innovation is becoming increasingly dependent on interdisciplinary research and on the crossing of institutional boundaries. This volume focuses on the conditions governing the supply of new medical technologies and suggest that the boundaries between disciplines, institutions, and the private and public sectors have been redrawn and reshaped. Individual essays explore the nature, organization, and management of interdisciplinary R&D in medicine; the introduction into clinical practice of the laser, endoscopic innovations, cochlear implantation, cardiovascular imaging technologies, and synthetic insulin; the division of innovating labor in biotechnology; the government- industry-university interface; perspectives on industrial R&D management; and the growing intertwining of the public and proprietary in medical technology. |
| emerging technologies in pharmaceutical industry: Pharmaceuticals and Personal Care Products: Waste Management and Treatment Technology Majeti Narasimha Vara Prasad, Meththika Vithanage, Atya Kapley, 2019-04-04 Pharmaceuticals and Personal Care Products Waste Management and Treatment Technology: Emerging Contaminants and Micro Pollutants provides the tools and techniques for identifying these contaminates and applying the most effective technology for their remediation, recovery and treatment. The consumption of pharmaceuticals and personal care products (PPCPs) has grown significantly over the last 35 years, thus increasing their potential risk to the environment. As PPCPs are very difficult to detect and remove using conventional wastewater treatment methods, this book provides solutions to a growing problem. - Includes sampling, analytical and characterization methods and technology for detecting PPCPs in the environment - Provides advanced treatment and disposal technologies for the removal of PPCPs from wastewater, surface water, landfills and septic systems - Examines the pathways of PPCPs into the environment |
| emerging technologies in pharmaceutical industry: Drying Technologies for Biotechnology and Pharmaceutical Applications Satoshi Ohtake, Ken-ichi Izutsu, David Lechuga-Ballesteros, 2020-02-10 A comprehensive source of information about modern drying technologies that uniquely focus on the processing of pharmaceuticals and biologicals Drying technologies are an indispensable production step in the pharmaceutical industry and the knowledge of drying technologies and applications is absolutely essential for current drug product development. This book focuses on the application of various drying technologies to the processing of pharmaceuticals and biologicals. It offers a complete overview of innovative as well as standard drying technologies, and addresses the issues of why drying is required and what the critical considerations are for implementing this process operation during drug product development. Drying Technologies for Biotechnology and Pharmaceutical Applications discusses the state-of-the-art of established drying technologies like freeze- and spray- drying and highlights limitations that need to be overcome to achieve the future state of pharmaceutical manufacturing. The book also describes promising next generation drying technologies, which are currently used in fields outside of pharmaceuticals, and how they can be implemented and adapted for future use in the pharmaceutical industry. In addition, it deals with the generation of synergistic effects (e.g. by applying process analytical technology) and provides an outlook toward future developments. -Presents a full technical overview of well established standard drying methods alongside various other drying technologies, possible improvements, limitations, synergies, and future directions -Outlines different drying technologies from an application-oriented point of view and with consideration of real world challenges in the field of drug product development -Edited by renowned experts from the pharmaceutical industry and assembled by leading experts from industry and academia Drying Technologies for Biotechnology and Pharmaceutical Applications is an important book for pharma engineers, process engineers, chemical engineers, and others who work in related industries. |
| emerging technologies in pharmaceutical industry: Therapeutic Antibody Engineering William R Strohl, Lila M Strohl, 2012-10-16 The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. - Goes beyond the standard engineering issues covered by most books and delves into structure-function relationships - Integration of knowledge across all areas of antibody engineering, development, and marketing - Discusses how current and future genetic engineering of cell lines will pave the way for much higher productivity |
| emerging technologies in pharmaceutical industry: Toxicity Testing in the 21st Century National Research Council, Division on Earth and Life Studies, Institute for Laboratory Animal Research, Board on Environmental Studies and Toxicology, Committee on Toxicity Testing and Assessment of Environmental Agents, 2007-10-05 Advances in molecular biology and toxicology are paving the way for major improvements in the evaluation of the hazards posed by the large number of chemicals found at low levels in the environment. The National Research Council was asked by the U.S. Environmental Protection Agency to review the state of the science and create a far-reaching vision for the future of toxicity testing. The book finds that developing, improving, and validating new laboratory tools based on recent scientific advances could significantly improve our ability to understand the hazards and risks posed by chemicals. This new knowledge would lead to much more informed environmental regulations and dramatically reduce the need for animal testing because the new tests would be based on human cells and cell components. Substantial scientific efforts and resources will be required to leverage these new technologies to realize the vision, but the result will be a more efficient, informative and less costly system for assessing the hazards posed by industrial chemicals and pesticides. |
| emerging technologies in pharmaceutical industry: Improving and Accelerating Therapeutic Development for Nervous System Disorders Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, 2014-02-06 Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials. |
| emerging technologies in pharmaceutical industry: Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade World Intellectual Property Organization, 2013 This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies. |
| emerging technologies in pharmaceutical industry: Research and Development in the Pharmaceutical Industry (A CBO Study) Congressional Budget Office, 2013-06-09 Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation... |
| emerging technologies in pharmaceutical industry: Pharmaceutical Biotechnology Gary Walsh, 2013-04-25 Pharmaceutical Biotechnology offers students taking Pharmacy and related Medical and Pharmaceutical courses a comprehensive introduction to the fast-moving area of biopharmaceuticals. With a particular focus on the subject taken from a pharmaceutical perspective, initial chapters offer a broad introduction to protein science and recombinant DNA technology- key areas that underpin the whole subject. Subsequent chapters focus upon the development, production and analysis of these substances. Finally the book moves on to explore the science, biotechnology and medical applications of specific biotech products categories. These include not only protein-based substances but also nucleic acid and cell-based products. introduces essential principles underlining modern biotechnology- recombinant DNA technology and protein science an invaluable introduction to this fast-moving subject aimed specifically at pharmacy and medical students includes specific ‘product category chapters’ focusing on the pharmaceutical, medical and therapeutic properties of numerous biopharmaceutical products. entire chapter devoted to the principles of genetic engineering and how these drugs are developed. includes numerous relevant case studies to enhance student understanding no prior knowledge of protein structure is assumed |
| emerging technologies in pharmaceutical industry: Information Technology in Pharmacy Stephen Goundrey-Smith, 2012-10-05 IT in Pharmacy: An Integrated Approach aims to describe and discuss the major areas of pharmacy IT innovation (e-prescribing, drug databases, electronic patient records, clinical decision support, pharmacy management systems, robots and automation etc) from a systems and a professional perspective. It will also consider how the areas of pharmacy IT link together and can be used to enable and develop pharmacy professional practice. The book will examine pharmacy IT from an international perspective, taking into account all parts of the world where IT systems are used in pharmacy practice – namely – North America, the UK, Western Europe and Australia – and will compare pharmacy IT in the different regions. This book is from the author of Principles of Electronic Prescribing (Springer, 2008) |
| emerging technologies in pharmaceutical industry: Artificial Intelligence in Drug Discovery Nathan Brown, 2020-11-04 Following significant advances in deep learning and related areas interest in artificial intelligence (AI) has rapidly grown. In particular, the application of AI in drug discovery provides an opportunity to tackle challenges that previously have been difficult to solve, such as predicting properties, designing molecules and optimising synthetic routes. Artificial Intelligence in Drug Discovery aims to introduce the reader to AI and machine learning tools and techniques, and to outline specific challenges including designing new molecular structures, synthesis planning and simulation. Providing a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia. |
| emerging technologies in pharmaceutical industry: Wharton on Managing Emerging Technologies George S. Day, Paul J. H. Schoemaker, 2004-08-20 Manager in allen Branchen werden mit dem Thema neue, zukunftsweisende Technologien konfrontiert. Hierher gehören nicht nur elektronische Technologien, sondern jede neue Technologie, die in der Lage ist, neue Industriezweige zu schaffen oder bestehende zu verändern. Diese Technologien sind ein neues Spiel, dessen Regeln unvereinbar sind mit Kultur und Geschäftsmethoden der meisten etablierten Unternehmen. Das erste Buch auf dem Markt, das sich mit diesem wichtigen Thema gezielt auseinandersetzt. Ein interdisziplinäres Expertenteam der Wharton School erläutert, wie Geschäftspraktiken geändert werden müssen, um Innovationen wie der Biotechnologie, der Informationstechnologie und dem Internet zu begegnen. Darüber hinaus wird diskutiert, wie Manager ihre Methoden zur Finanzanalyse, Markteinschätzung und zur Wettbewerbsstrategie ändern müssen, und wie etablierte Firmen künftig die gängigen Fehler im Zusammenhang mit neuen Technologien vermeiden können. |
| emerging technologies in pharmaceutical industry: Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, 2012-04-04 The development and application of regulatory science - which FDA has defined as the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products - calls for a well-trained, scientifically engaged, and motivated workforce. FDA faces challenges in retaining regulatory scientists and providing them with opportunities for professional development. In the private sector, advancement of innovative regulatory science in drug development has not always been clearly defined, well coordinated, or connected to the needs of the agency. As a follow-up to a 2010 workshop, the IOM held a workshop on September 20-21, 2011, to provide a format for establishing a specific agenda to implement the vision and principles relating to a regulatory science workforce and disciplinary infrastructure as discussed in the 2010 workshop. |
| emerging technologies in pharmaceutical industry: The Fourth Industrial Revolution Klaus Schwab, 2017-01-03 World-renowned economist Klaus Schwab, Founder and Executive Chairman of the World Economic Forum, explains that we have an opportunity to shape the fourth industrial revolution, which will fundamentally alter how we live and work. Schwab argues that this revolution is different in scale, scope and complexity from any that have come before. Characterized by a range of new technologies that are fusing the physical, digital and biological worlds, the developments are affecting all disciplines, economies, industries and governments, and even challenging ideas about what it means to be human. Artificial intelligence is already all around us, from supercomputers, drones and virtual assistants to 3D printing, DNA sequencing, smart thermostats, wearable sensors and microchips smaller than a grain of sand. But this is just the beginning: nanomaterials 200 times stronger than steel and a million times thinner than a strand of hair and the first transplant of a 3D printed liver are already in development. Imagine “smart factories” in which global systems of manufacturing are coordinated virtually, or implantable mobile phones made of biosynthetic materials. The fourth industrial revolution, says Schwab, is more significant, and its ramifications more profound, than in any prior period of human history. He outlines the key technologies driving this revolution and discusses the major impacts expected on government, business, civil society and individuals. Schwab also offers bold ideas on how to harness these changes and shape a better future—one in which technology empowers people rather than replaces them; progress serves society rather than disrupts it; and in which innovators respect moral and ethical boundaries rather than cross them. We all have the opportunity to contribute to developing new frameworks that advance progress. |
| emerging technologies in pharmaceutical industry: FDA in the Twenty-First Century Holly Fernandez Lynch, I. Glenn Cohen, 2015-09-08 In its decades-long effort to assure the safety, efficacy, and security of medicines and other products, the Food and Drug Administration has struggled with issues of funding, proper associations with industry, and the balance between consumer choice and consumer protection. Today, these challenges are compounded by the pressures of globalization, the introduction of novel technologies, and fast-evolving threats to public health. With essays by leading scholars and government and private-industry experts, FDA in the Twenty-First Century addresses perennial and new problems and the improvements the agency can make to better serve the public good. The collection features essays on effective regulation in an era of globalization, consumer empowerment, and comparative effectiveness, as well as questions of data transparency, conflicts of interest, industry responsibility, and innovation policy, all with an emphasis on pharmaceuticals. The book also intervenes in the debate over off-label drug marketing and the proper role of the FDA before and after a drug goes on the market. Dealing honestly and thoroughly with the FDA's successes and failures, these essays rethink the structure, function, and future of the agency and the effect policy innovations may have on regulatory institutions abroad. |
| emerging technologies in pharmaceutical industry: Leading Pharmaceutical Innovation Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer, 2018-05-10 Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D. |
| emerging technologies in pharmaceutical industry: Smart Systems for Industrial Applications C. Venkatesh, N. Rengarajan, P. Ponmurugan, S. Balamurugan, 2022-01-07 SMART SYSTEMS FOR INDUSTRIAL APPLICATIONS The prime objective of this book is to provide an insight into the role and advancements of artificial intelligence in electrical systems and future challenges. The book covers a broad range of topics about AI from a multidisciplinary point of view, starting with its history and continuing on to theories about artificial vs. human intelligence, concepts, and regulations concerning AI, human-machine distribution of power and control, delegation of decisions, the social and economic impact of AI, etc. The prominent role that AI plays in society by connecting people through technologies is highlighted in this book. It also covers key aspects of various AI applications in electrical systems in order to enable growth in electrical engineering. The impact that AI has on social and economic factors is also examined from various perspectives. Moreover, many intriguing aspects of AI techniques in different domains are covered such as e-learning, healthcare, smart grid, virtual assistance, etc. Audience The book will be of interest to researchers and postgraduate students in artificial intelligence, electrical and electronic engineering, as well as those engineers working in the application areas such as healthcare, energy systems, education, and others. |
| emerging technologies in pharmaceutical industry: Chemical Engineering in the Pharmaceutical Industry David J. am Ende, 2011-03-10 This book deals with various unique elements in the drug development process within chemical engineering science and pharmaceutical R&D. The book is intended to be used as a professional reference and potentially as a text book reference in pharmaceutical engineering and pharmaceutical sciences. Many of the experimental methods related to pharmaceutical process development are learned on the job. This book is intended to provide many of those important concepts that R&D Engineers and manufacturing Engineers should know and be familiar if they are going to be successful in the Pharmaceutical Industry. These include basic analytics for quantitation of reaction components– often skipped in ChE Reaction Engineering and kinetics books. In addition Chemical Engineering in the Pharmaceutical Industry introduces contemporary methods of data analysis for kinetic modeling and extends these concepts into Quality by Design strategies for regulatory filings. For the current professionals, in-silico process modeling tools that streamline experimental screening approaches is also new and presented here. Continuous flow processing, although mainstream for ChE, is unique in this context given the range of scales and the complex economics associated with transforming existing batch-plant capacity. The book will be split into four distinct yet related parts. These parts will address the fundamentals of analytical techniques for engineers, thermodynamic modeling, and finally provides an appendix with common engineering tools and examples of their applications. |
| emerging technologies in pharmaceutical industry: Pharmaceutical Formulation Geoffrey D Tovey, 2018-06-25 Formulation is a key step in the drug design process, where the active drug is combined with other substances that maximise the therapeutic potential, safety and stability of the final medicinal product. Modern formulation science deals with biologics as well as small molecules. Regulatory and quality demands, in addition to advances in processing technologies, result in growing challenges as well as possibilities for the field. Pharmaceutical Formulation provides an up to date source of information for all who wish to understand the principles and practice of formulation in the drug industry. The book provides an understanding of the links between formulation theory and the practicalities of processing in a commercial environment, giving researchers the knowledge to produce effective pharmaceutical products that can be approved and manufactured. The first chapters introduce readers to different dosage forms, including oral liquid products, topical products and solid dosage forms such as tablets and capsules. Subsequent chapters cover pharmaceutical coatings, controlled release drug delivery and dosage forms designed specifically for paediatric and geriatric patients. The final chapter provides an introduction to the vital role intellectual property plays in drug development. Covering modern processing methods and recent changes in the regulatory and quality demands of the industry, Pharmaceutical Formulation is an essential, up to date resource for students and researchers working in academia and in the pharmaceutical industry. |
| emerging technologies in pharmaceutical industry: Novel Drug Delivery Technologies Ambikanandan Misra, Aliasgar Shahiwala, 2020-02-12 The application of drug delivery is a valuable, cost-effective lifecycle management resource. By endowing drugs with new and innovative therapeutic benefits, drug delivery systems extend products’ profitable lifecycle, giving pharmaceutical companies competitive and financial advantages, and providing patients with improved medications. Formulation development is now being used to create new dosage forms for existing products, which not only reduces the time and expense involved in new drug development, but also helps with regard to patent protection and bypassing existing patents. Today’s culture demands convenience, a major factor determining adherence to drug therapy. Over the past few years, patient convenience-oriented research in the field of drug delivery has yielded a range of innovative drug-delivery options. As a result, various drug-delivery systems, including medicated chewing gums, oral dispersible tablets, medicated lozenges and lollipops, have now hit the market and are very popular. These dosage forms offer a highly convenient way to dose medications, not only for special population groups with swallowing difficulties, such as children and the elderly, but for the general populace as well. This book provides valuable insights into a number of formulation design approaches that are currently being used, or could be used, to provide new benefits from existing drug molecules. |
| emerging technologies in pharmaceutical industry: Hot-Melt Extrusion Dennis Douroumis, 2012-04-24 Hot-melt extrusion (HME) - melting a substance and forcing it through an orifice under controlled conditions to form a new material - is an emerging processing technology in the pharmaceutical industry for the preparation of various dosage forms and drug delivery systems, for example granules and sustained release tablets. Hot-Melt Extrusion: Pharmaceutical Applications covers the main instrumentation, operation principles and theoretical background of HME. It then focuses on HME drug delivery systems, dosage forms and clinical studies (including pharmacokinetics and bioavailability) of HME products. Finally, the book includes some recent and novel HME applications, scale -up considerations and regulatory issues. Topics covered include: principles and die design of single screw extrusion twin screw extrusion techniques and practices in the laboratory and on production scale HME developments for the pharmaceutical industry solubility parameters for prediction of drug/polymer miscibility in HME formulations the influence of plasticizers in HME applications of polymethacrylate polymers in HME HME of ethylcellulose, hypromellose, and polyethylene oxide bioadhesion properties of polymeric films produced by HME taste masking using HME clinical studies, bioavailability and pharmacokinetics of HME products injection moulding and HME processing for pharmaceutical materials laminar dispersive & distributive mixing with dissolution and applications to HME technological considerations related to scale-up of HME processes devices and implant systems by HME an FDA perspective on HME product and process understanding improved process understanding and control of an HME process with near-infrared spectroscopy Hot-Melt Extrusion: Pharmaceutical Applications is an essential multidisciplinary guide to the emerging pharmaceutical uses of this processing technology for researchers in academia and industry working in drug formulation and delivery, pharmaceutical engineering and processing, and polymers and materials science. This is the first book from our brand new series Advances in Pharmaceutical Technology. Find out more about the series here. |
| emerging technologies in pharmaceutical industry: The Role of NIH in Drug Development Innovation and Its Impact on Patient Access National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, 2020-01-27 To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop. |
| emerging technologies in pharmaceutical industry: Artificial Intelligence in Healthcare Adam Bohr, Kaveh Memarzadeh, 2020-06-21 Artificial Intelligence (AI) in Healthcare is more than a comprehensive introduction to artificial intelligence as a tool in the generation and analysis of healthcare data. The book is split into two sections where the first section describes the current healthcare challenges and the rise of AI in this arena. The ten following chapters are written by specialists in each area, covering the whole healthcare ecosystem. First, the AI applications in drug design and drug development are presented followed by its applications in the field of cancer diagnostics, treatment and medical imaging. Subsequently, the application of AI in medical devices and surgery are covered as well as remote patient monitoring. Finally, the book dives into the topics of security, privacy, information sharing, health insurances and legal aspects of AI in healthcare. - Highlights different data techniques in healthcare data analysis, including machine learning and data mining - Illustrates different applications and challenges across the design, implementation and management of intelligent systems and healthcare data networks - Includes applications and case studies across all areas of AI in healthcare data |
| emerging technologies in pharmaceutical industry: Applied Ethics in a Digital World Vasiliu-Feltes, Ingrid, Thomason, Jane, 2021-11-19 As advances in disruptive technologies transform politics and increase the velocity of information and policy flows worldwide, the public is being confronted with changes that move faster than they can comprehend. There is an urgent need to analyze and communicate the ethical issues of these advancements. In a perpetually updating digital world, data is becoming the dominant basis for reality. This new world demands a new approach because traditional methods are not fit for a non-physical space like the internet. Applied Ethics in a Digital World provides an analysis of the ethical questions raised by modern science, technological advancements, and the fourth industrial revolution and explores how to harness the speed, accuracy, and power of emerging technologies in policy research and public engagement to help leaders, policymakers, and the public understand the impact that these technologies will have on economies, legal and political systems, and the way of life. Covering topics such as artificial intelligence (AI) ethics, digital equity, and translational ethics, this book is a dynamic resource for policymakers, civil society, CEOs, ethicists, technologists, security advisors, sociologists, cyber behavior specialists, criminologists, data scientists, global governments, students, researchers, professors, academicians, and professionals. |
| emerging technologies in pharmaceutical industry: Innovation in Pharmacy: Advances and Perspectives. September 2018 Organizer Committee IPAP18 – Salamanca, 2018-09-21 This book contains the summaries of the Innovation in Pharmacy: Advances and Perspectives that took place in Salamanca (Spain) in September 2018. The early science of chemistry and microbiology were the source of most drugs until the revolution of genetic engineering in the mid 1970s. Then biotechnology made available novel protein agents such as interferons, blood factors and monoclonal antibodies that have changed the modern pharmacy. Over the past year, a new pharmacy of oligonucleotides has emerged from the science of gene expression such as RNA splicing and RNA interference. The ability to design therapeutic agents from genomic sequences will transform treatment for many diseases. The science that created this advance and its future promise will be discussed. Phillip Allen Sharp is an American geneticist and molecular biologist who co-discovered RNA splicing. He shared the 1993 Nobel Prize in Physiology or Medicine with Richard J. Roberts for “the discovery that genes in eukaryotes are not contiguous strings but contain introns, and that the splicing of messenger RNA to delete those introns can occur in different ways, yielding different proteins from the same DNA sequence. He works in Institute Professor Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, US. Este libro recoge los resúmenes de la «Innovation in Pharmacy: Advances and Perspectives» que tuvo lugar en Salamanca (España) en septiembre de 2018. La ciencia primitiva de la química y la microbiología fue la fuente de la mayoría de las drogas hasta la revolución de la ingeniería genética a mediados de la década de 1970. Luego, la biotecnología puso a disposición agentes proteínicos novedosos como interferones, factores sanguíneos y anticuerpos monoclonales que han cambiado la farmacia moderna. Durante el año pasado, surgió una nueva farmacia de oligonucleótidos a partir de la ciencia de la expresión génica, como el empalme de ARN y la interferencia de ARN. La capacidad de diseñar agentes terapéuticos a partir de secuencias genómicas transformará el tratamiento de muchas enfermedades. La ciencia que creó este avance y su promesa futura será discutida. Phillip Allen Sharp es un genetista y biólogo molecular estadounidense que co-descubrió el empalme de ARN. Compartió el Premio Nobel de 1993 en Fisiología o Medicina con Richard J. Roberts por el descubrimiento de que los genes en eucariotas no son cadenas contiguas, sino que contienen intrones, y que el empalme del ARN mensajero para eliminar esos intrones puede ocurrir de diferentes maneras, produciendo diferentes proteínas de la misma secuencia de ADN. Trabaja en el Instituto Profesor Koch Institute for Integrative Cancer Research, Instituto Tecnológico de Massachusetts (MIT), Cambridge, MA, EE. UU. |
| emerging technologies in pharmaceutical industry: Innovation and Invention in Medical Devices Institute of Medicine, Board on Health Sciences Policy, Roundtable on Research and Development of Drugs, Biologics, and Medical Devices, 2001-12-01 The objective of the workshop that is the subject of this summary report was to present the challenges and opportunities for medical devices as perceived by the key stakeholders in the field. The agenda, and hence the summaries of the presentations that were made in the workshop and which are presented in this summary report, was organized to first examine the nature of innovation in the field and the social and economic infrastructure that supports such innovation. The next objective was to identify and discuss the greatest unmet clinical needs, with a futuristic view of technologies that might meet those needs. And finally, consideration was given to the barriers to the application of new technologies to meet clinical needs. |
| emerging technologies in pharmaceutical industry: Serial Innovators Abbie Griffin, Raymond L. Price, Bruce Vojak, 2012-05-30 Serial Innovators: How Individuals Create and Deliver Breakthrough Innovations in Mature Firms zeros in on the cutting-edge thinkers who repeatedly create and deliver breakthrough innovations and new products in large, mature organizations. These employees are organizational powerhouses who solve consumer problems and substantially contribute to the financial value to their firms. In this pioneering study, authors Abbie Griffin, Raymond L. Price, and Bruce A. Vojak detail who these serial innovators are and how they develop novel products, ranging from salt-free seasonings to improved electronics in companies such as Alberto Culver, Hewlett-Packard, and Procter & Gamble. Based on interviews with over 50 serial innovators and an even larger pool of their co-workers, managers and human resources teams, the authors reveal key insights about how to better understand, emulate, enable, support, and manage these unique and important individuals for long-term corporate success. Interestingly, the book finds that serial innovators are instrumental both in cases where firms are aware of clear market demands, and in scenarios when companies take risks on new investments, creating a consumer need. For over 25 years, research on innovation has taken the perspective that new product development can be managed like any other (complex) process of the firm. While a highly structured and closely supervised approach is helpful in creating incremental innovations, this book finds that it is not conducive to creating breakthrough innovations. The text argues that the drive to routinize innovation has gone too far; in fact, so far as to limit many mature firms' ability to create breakthrough innovations. In today's economy, with the future of so many large firms on the line, this book is a clarion call to businesses to rethink how to nurture and thrive on their innovative workforce. |
| emerging technologies in pharmaceutical industry: Countering the Problem of Falsified and Substandard Drugs Institute of Medicine, Board on Global Health, Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, 2013-06-20 The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines. |
| emerging technologies in pharmaceutical industry: Troubleshooting the Extrusion Process María del Pilar Noriega E., Chris Rauwendaal, 2019-10-07 Troubleshooting extrusion problems is one of the most challenging tasks in extrusion operations, requiring a good understanding of the extrusion process and the material properties, good instrumentation, good analysis tools, and a systematic and logical approach. This book addresses all issues crucial in extrusion troubleshooting. Additionally, it includes industrial case studies, richly illustrated with photographs and photomicrographs, used to provide exemplary approaches to efficient problem analysis and problem solving. The interconnectivity between the different relevant knowledge areas such as materials engineering, processing technology, and product development is emphasized. This revised third edition comprises a very significant update, with a great deal of new content, especially focusing on additional case studies as well as new sections on collection and interpretation of extrusion process data, rotational rheometry, the smartphone, how screw design can affect extruder performance, melt temperature variation, recent research on automatic optimization of extruder barrel temperatures, process signal analysis using Fast Fourier Transform, among other topics. |
How the Top 10 Emerging Technologies of 2024 will impact the …
Jun 25, 2024 · The World Economic Forum's Top 10 Emerging Technologies of 2024 report lists this year's most impactful emerging technologies. The list includes ways artificial intelligence is …
Top 10 Emerging Technologies of 2024 | World Economic Forum
Jun 25, 2024 · These emerging technologiesare disruptive, attractive to investors and researchers, and expected to achieve considerable scale within five years. This edition …
Unlocking clean energy investment in emerging markets
Apr 21, 2025 · Emerging economies and developing countries house over half the world’s population, but receive less than 15% of global clean energy investments. Investors often …
The Future of Jobs Report 2025 - World Economic Forum
Jan 7, 2025 · Increasing geoeconomic fragmentation, coupled with the rapid adoption of new technologies and expansion of digital access, has significantly increased cybersecurity …
Discover the must-read cybersecurity stories of the past month
Feb 19, 2025 · This highlights the gap between awareness of AI risks and its unchecked adoption, adding to the growing complexity of cyberspace, where emerging technologies, geopolitical …
The top technology stories from 2024 - The World Economic Forum
Dec 18, 2024 · In June 2024, the Forum released its Top 10 Emerging Technologies of 2024 report. Drawing on insights from scientists, researchers and futurists, the report identifies 10 …
Global Cybersecurity Outlook 2025 | World Economic Forum
Jan 13, 2025 · The Global Cybersecurity Outlook 2025 highlights key trends shaping economies and societies in 2025, along with insights into emerging threats and solutions.
Emerging Technologies | World Economic Forum
6 days ago · Emerging Technologies. 6,217 Stories. Emerging Technologies Entrepreneurship for a New Era. Jun 26, 2025 ...
'Industries in the Intelligent Age': AI, tech & more at Davos 2025
Jan 20, 2025 · These emerging technologiesare disruptive, attractive to investors and researchers, and expected to achieve considerable scale within five years. This edition …
How the top 10 emerging technologies of 2023 will affect us
Jun 26, 2023 · Other emerging technologies range from innovations harnessing the power of AI to reengineering molecular biology. Technology is a relentless disruptor. It changes the context …
NEW INDUSTRIAL MEDICAL DEVICES INDUSTRY
aerospace, pharmaceutical and medical devices sectors Develop entire ecosystem to support the high value-added activities Build strong local SMEs in manufacturing and related services to …
International Journal of Pharmaceutics - U.S. Food and Drug …
Sep 7, 2016 · collaborators that focus on emerging technologies including process analytical technology (PAT), advanced process controls, real-timereleasetesting, and process simulation …
Data Driven Digital Transformation Pharmaceutical Supply …
pharmaceutical supply chain – building trust in both individual brands, and the Digital transformation pharmaceutical industry. Active management of data is no longer optional in …
Innovation and Regulatory Landscape: Emerging …
Apr 3, 2019 · therapies for patients and modernizing pharmaceutical manufacture • FDA supports the implementation of innovative technologies using a science and risk-based approach • The …
Emerging from disruption: The future of pharma operations …
given that the industry has long created value largely through revenue expansion rather than through cost savings. Exhibit 2 Pharmaceutical industry trends and implications Current …
Program on the Pharmaceutical Industry (POPI) - MIT
Research Strategy and Research Productivity in the Pharmaceutical Industry”, Rand Journal of Economics. 1996. Rosenthal, Meredith B., Ernst R. Berndt, Julie M. Donohue, Richard G. …
The Innovation Imperative: Pioneering New Modalities for …
advises pharmaceutical companies to address complex industry challenges through a long-term, transformative approach across four strategic domains. In particular, the report stresses the …
India Pharma Inc. - PwC
regulatory hurdles and the emerging technologies that need to be considered in order to achieve a sustainable and compliant long-term growth. We hope this report presents an overview of …
Advanced Manufacturing Technologies Designation Program …
102 interested in implementing emerging or advanced technologies in drug development and are ... International Council for Harmonisation guidance for industry Q8(R2) Pharmaceutical …
Remote Observation Technologies in the Pharmaceutical
Emerging network-based video solutions have the potential to improve operations in the pharmaceutical manufacturing space. With that said, the industry needs guidance from …
Office of Pharmaceutical Quality 2023 Annual Report - U.S.
In 2023, OPQ supported the release of 10 guidance documents for industry ... engagement with stakeholders developing emerging pharmaceutical technologies prior to a regulatory …
The Future of Compliance in the Pharmaceutical Industry
2 PwC The Future of Compliance in the Pharmaceutical Industry Compliance in the pharmaceutical industry is being transformed principally by six key external forces: legal, …
Emerging Technologies in 3D Printing of Pharmaceuticals
Oct 3, 2019 · Benefits for Pharmaceutical Industry Dosage forms with unique properties –Instant dispersion –Ultra low dose –Complex release profiles –Combination therapy –Anti-counterfeit …
Digitization, automation, and online testing: The future of …
All these are currently available technologies, with time to impact as short as three months for each case. An average chemical QC lab can reduce costs by 25 to 45 percent by reaching the …
FDA's Strategy Document on Innovative Manufacturing …
1. 1 . FDA’s Strategy Document on . 2 . Innovative Manufacturing Technologies . 3 . 4 . 5 . I. Executive Summary 6 . 7 As part of the Prescription Drug User Fee Act (PDUFA) …
Digitalization enhancement in the pharmaceutical supply
Emerging digital-based technologies in the pharmaceutical supply chain Studies on the emerging digital-based technologies in the pharmaceutical supply chain in Google Scholar (period of …
H EALTH CARE INDUSTRY Medical Devices MARKET UPDATE …
Dec 5, 2003 · Just as DES and cardiac rhythm management (CRM) technologies altered the medical device industry landscape, analysts believe new technologies such as percutaneous …
Guidance for Industry - U.S. Food and Drug Administration
pharmaceutical manufacturing and regulation may be characterized as follows: Product quality and performance are ensured through the design of effective and efficient manufacturing …
Upcoming Challenges in Intellectual Property Presented By …
medicine R&D in pharmaceutical industry. Namely, if sufficient intellectual property protection is not secured for the regenerative medicine and stem cell technologies, there will be a lower …
The Impact of Emerging Technologies on Pharmaceutical …
Emerging technologies present a transformative potential for pharmaceutical process design and optimization, particularly within Africa’s evolving pharmaceutical industries. The purpose of this
Pharmaceutical Up-Front Licensing Fees - plg-group.com
entry and emerging pharmaceuti-cals, along with a theoretical discus-sion on why up-front fees should be considered as a part of every license. The same up-front fee discussion applies to …
h Opportunities and challenges for Indian Pharmaceutical …
newer drugs, the future of global pharma industry is bright. While in developed countries growth is flat due to the prevailing healthcare challenges, emerging mar-kets continue to grow …
PART II TECHNOLOGY AND CONSUMER PRODUCT …
has focused on developing emerging technologies such as artificial intelligence (AI), quantum technologies, biotechnology, and battery energy storage systems. The United States has …
ARTICLES PHARMACEUTICAL - Journal on Emerging …
Sep 4, 2023 · NOTRE DAME JOURNAL ON EMERGING TECHNOLOGIES [Vol. 4:94] in innovation and resulting market dominance of large pharmaceutical companies has brought …
Future of Pharmaceutical Quality and the Path to Get There
Feb 3, 2017 · Pharmaceutical cGMPs for the 21st Century 2004: PAT Guidance . 2006: ICH Q9 2008: ICH Q10 2009: ICH Q8 . 2011: Process Validation Guidance . 2012: ICH Q11 . 2013: …
Emerging Technologies for Wastewater Treatment and In …
Emerging Technologies for Wastewater Treatment and In-Plant Wet Weather Management Prepared for: Office of Wastewater Management ... Guidance was contributed by the following …
PHARMACEUTICAL PACKAGING: CURRENT TRENDS AND …
“Need is mother of all Inventions”, phrase is best describing the emerging technologies towards pharmaceutical packaging. Indian Packaging market is expected to grow up to US$ 55 billion …
Emerging chemistry technologies for a better world - Nature
IUPAC Top Ten Emerging Technologies in Chemistry 2021 ... quite attractive for the pharmaceutical industry. The analysis of the microbiome could lead to better understanding of …
A COLLABORATIVE APPROACH TO IMPROVE GLOBAL HEALTH
for transferring R&D pharmaceutical technologies. Through regulation and investment, governments can help to create the right conditions for technology markets to function. For the …
Emerging Technology as a Key Enabler for Modernizing …
turing technologies have revolutionized other indus-trial sectors (e.g., electronics and chemicals), and strategic implementation of these technologies in the pharmaceutical industry could well …
A STUDY ON FINANCIAL PERFORMANCE OF INDIAN …
Abstract: This study attempts to measure the financial performance of the Indian Pharmaceutical industry taking into consideration the top six Indian Pharma companies for a period of five …
Assessing the critical success factors for implementing …
The emerging technologies of Industry 4.0 (I4.0) are crucial to incorporating agility, sustain-ability, smartness, and competitiveness in the business model, enabling long-term sustain- ... RQ1: …
A Comparative Analysis Of Digital Marketing Strategies In The ...
Emerging Technologies (e.g., Virtual Reality and Augmented Reality): Exploration of emerging ... The pharmaceutical industry in the Delhi-NCR region is experiencing a dynamic shift towards …
WILL DIGITAL PLATFORMS TRANSFORM …
pharmaceutical industry’s value chain. Long, capital-intensive development cycles and legacy processes, though, have made it difficult to exploit the full potential of emerging digital …
PHARMACEUTICAL AND BIOMEDICAL PROJECT …
p. ; cm.—(Wiley series on technologies for the pharmaceutical industry) Includes index. ISBN 978-0-470-29341-6 (hardback) 1. Project management. 2. Pharmaceutical industry. 3. Medical …
Emerging Industries in Jamaica - Institute of Jamaica
around a new product or idea that is in the early stages of development. An emerging industry typically consists of just a few companies and is often centred around new technology”.5 …
Pharma outlook 2030: From evolution to revolution - KPMG
technologies, the pharmaceutical industry needs to reimagine its future. By 2030, we should not simply expect more targeted therapies, practitioners will also be able to predict the likelihood of …
ISSN: 2277- 7695 Technology transfer in pharmaceutical …
Technology transfer in pharmaceutical industry Remya Mariam John Abstract In today’s business setting, interest in the profitable exploitation of a firm’s technological assets, through ...
Office of Pharmaceutical Quality 2023 Annual Report - U.S.
In 2023, OPQ supported the release of 10 guidance documents for industry ... engagement with stakeholders developing emerging pharmaceutical technologies prior to a regulatory …
A Review on Advanced Treatment of Pharmaceutical …
In recent years, the fast development of pharmaceutical industry has become an important part of China’s national economy. In 2014, the output of chemical original medicine had reached 3.034 …
McKinsey Technology Trends Outlook 2022 - McKinsey
1Relevance estimated qualitatively by industry experts based on trend’s potential to affect an industry; degree of relevance is scaled at both trend and industry levels. Silicon Age …
Pharmaceutical Sciences/ Pharmaceutics (M.S.)
Thesis Option, and the Ph.D. in Pharmaceutical Sciences with a concentration in Pharmaceutics. The program is designed to prepare students for positions in the pharmaceutical industry, …
The top trends in tech—executive summary download
convergences between technologies, startling breakthroughs in health and materials sciences, astonishing new product ... not exhaustive; 2. Includes Industry 4.0 (debate exists as to …
The Globalization of the Pharmaceutical Industry: Trends
The pharmaceutical industry is undergoing original expansion, with emerging markets playing a pivotal role in this growth. Countries such as India, China, and Brazil are becoming key players …
The Advanced Manufacturing Technologies Designation …
Technologies Designation Program Ranjani Prabhakara, Ph.D. ... Sec. 3203 Emerging Technology Program ... pharmaceutical industry
QUALITY RISK MANAGEMENT Q9(R1) - ICH
The importance of quality systems has been recognized in the pharmaceutical 8 industry and it is evident that quality risk management is a valuable component of an effective 9 ... 40 The …
Upcoming challenges in intellectual property presented by …
a hot topic in pharmaceutical industry. This ... Upcoming challenges in IP presented by emerging pharmaceutical technologies Editorial to stem cells, and properly differentiated to the tis-
Advancing the Utilization and Supporting the Implementation …
The Robert J. Margolis, MD, Center for Health Policy is part of Duke University, and as such it honors the tradition of academic independence on the part of its faculty and
CSET - Chinese Government Guidance Funds
Dec 15, 2018 · strategic and emerging technologies. Government agencies at central, provincial, and local levels establish guidance funds. This typically involves creating the fund, ... “A …
